THE SCIENCE OF ADVANCED
An effective vaccine for equine herpesvirus type-1.
- EHV-1, or rhino, can cause respiratory tract infections, epidemic abortions in mares, the birth of non-viable foals and sporadic neurological disease. This vaccine does not have a label claim for neurological disease protection.
- An inactivated, concentrated, adjuvanted, tissue culture origin equine herpesvirus type-1 (EHV-1) vaccine
- Advanced filtration process through the Antigen Purification System (APS™)
- Exceptional safety profile with the exclusive Havlogen® Adjuvant
This product has been shown to be effective for the vaccination of healthy horses 6 months of age or older against abortion and respiratory disease caused by EHV-1. Duration of immunity has not been established. For more information regarding safety and efficacy data, go to productdata.aphis.usda.gov.
For pregnant mares administer a 2 mL dose intramuscularly in the 5th, 7th and 9th months of pregnancy. Three doses are essential for primary immunization. Maiden and barren mares housed or pastured with pregnant mares should be vaccinated on the same schedule. For primary vaccination against respiratory disease administer three 2 mL doses intramuscularly at 4 to 6 week intervals. Historically, annual revaccination with this product has been recommended. The need for this booster has not been established. For more information on revaccination frequency, consult your veterinarian.
Learn more about the updated line of PRESTIGE vaccines.
A guide to the entire equine product line from Merck Animal Health.
Elevating expectations for equine herpesvirus protection.
No items to show.